MET and non-small cell lung carcinoma: Notably, MET-amplified NSCLC patients have been observed to benefit from certain targeted inhibitors, such as crizotinib; however, the magnitude of benefit is below what is observed with other driver alterations, highlighting the relevance of defining and harmonizing the cutoff (51–55).